[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100434215":3},{"organization":4,"armGroups":7,"interventions":25,"overallOfficials":42,"centralContacts":46,"locations":56,"responsibleParty":73,"collaborators":41,"id":76,"slug":77,"hasResults":78,"nctId":79,"briefTitle":80,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":78,"sex":83,"minAge":84,"maxAge":85,"enrollmentInfo":86,"targetDuration":41,"studyType":89,"phases":90,"briefSummary":92,"conditions":93,"keywords":41,"overallStatus":58,"whyStopped":41,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":109},{"fullName":5,"class":6},"University of Kansas Medical Center","OTHER",[8,14,20],{"label":9,"type":10,"description":11,"interventionNames":12},"Placebo","PLACEBO_COMPARATOR","KU Investigational Pharmacy will provide the drug prescription bottle with 35-day supply of placebo to the research coordinator to give to the research participant.\n\nThe placebo is an inert substance with no intended medical value and is used as a negative control for comparison with the study drug.\n\nParticipants will receive a Placebo Pill; has no active ingredients but is made to look like the study drug.",[13],"Drug: Placebo",{"label":15,"type":16,"description":17,"interventionNames":18},"Clonidine","EXPERIMENTAL","KU Investigational Pharmacy will provide the drug prescription bottle with 35-day supply of clonidine to the research coordinator to give to the research participant.\n\nPlanned use in this study\n\n1. Condition\u002Fdisease indication(s): Vascular function and blood flow\n2. Subject population: Hypertension\n3. Dose(s): 0.1 mg (oral)\n4. Administration: Oral\n5. Dosing regimen: 0.1 mg twice daily by mouth",[19],"Drug: Clonidine Pill",{"label":21,"type":16,"description":22,"interventionNames":23},"Hydrochlorothiazide (HCTZ)","KU Investigational Pharmacy will provide the drug prescription bottle with 35-day supply of Hydrochlorothiazide to the research coordinator to give to the research participant.\n\nPlanned use in this study\n\n1. Condition\u002Fdisease indication(s): Hypertension\n2. Subject population: Hypertension\n3. Dose(s): 25 mg\u002Fday\n4. Administration: Oral\n5. Dosing regimen: 12.5 mg twice per day",[24],"Drug: Hydrochlorothiazide 12.5Mg Tab",[26,33,38],{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"DRUG","Hydrochlorothiazide 12.5Mg Tab","Will receive 4 week supply (35 days) of Hydrochlorothiazide Pills (12.5 mg twice a day)\n\nPlanned use in this study\n\n1. Condition\u002Fdisease indication(s): Hypertension\n2. Subject population: Hypertension\n3. Dose(s): 25 mg\u002Fday\n4. Administration: Oral\n5. Dosing regimen: 12.5 mg twice per day",[21],[32],"Hydrochlorothiazide",{"type":27,"name":34,"description":35,"armGroupLabels":36,"otherNames":37},"Clonidine Pill","Will receive 4 week supply (35 days) of Clonidine Pills (0.1 mg twice\u002Fday)\n\nPlanned use in this study\n\n1. Condition\u002Fdisease indication(s): Vascular function and blood flow\n2. Subject population: Hypertension\n3. Dose(s): 0.1 mg (oral)\n4. Administration: Oral\n5. Dosing regimen: 0.1 mg twice daily by mouth",[15],[15],{"type":27,"name":9,"description":39,"armGroupLabels":40,"otherNames":41},"Will receive a 4 week supply (35 days) of Placebo Pills; has no active ingredients but is made to look like the study drug.",[9],null,[43],{"name":44,"affiliation":5,"role":45},"Seth W. W Holwerda, PhD","PRINCIPAL_INVESTIGATOR",[47,52],{"name":48,"role":49,"phone":50,"phoneExt":41,"email":51},"Seth W Holwerda, Ph,D","CONTACT","9729223230","sholwerda@kumc.edu",{"name":53,"role":49,"phone":54,"phoneExt":41,"email":55},"Davina A Clonch","9132266009","dclonch@kumc.edu",[57],{"facility":5,"status":58,"city":59,"state":60,"zip":61,"country":62,"countryCode":63,"cosmosGeoPoint":64,"geoPoint":69,"contacts":70},"RECRUITING","Kansas City","Kansas","66103","United States","US",{"type":65,"coordinates":66},"Point",[67,68],-94.62746,39.11417,{"lat":68,"lon":67},[71],{"name":72,"role":49,"phone":50,"phoneExt":41,"email":51},"Seth W. W Holwerda",{"type":45,"investigatorFullName":74,"investigatorTitle":75,"investigatorAffiliation":5,"oldNameTitle":41,"oldOrganization":41},"Seth Holwerda PhD","Principal Investigator","100434215","phase-1-mitigating-the-pro-inflammatory-phenotype-of-obesity-100434215",false,"NCT04934228","Mitigating the Pro-inflammatory Phenotype of Obesity","MAPLE","Inclusion Criteria:\n\n* Male or Female, age 18-79\n* Obese: BMI \\> 30 m\u002Fkg2\n* Hypertensive: blood pressure \\>130\u002F80\n* Elevated insulin resistance (HOMA-IR \\> 2.5)\n* Waist circ: \\>102 cm (men) and \\>88 cm (women)\n* Fasting glucose \\\u003C 126 mg\u002FdL\n* Fasting triglycerides \\\u003C 250 mg\u002FdL\n* HbA1c \\\u003C 6.5%\n* Willing to visit research lab (Fairway CTSU)\n* Willing to undergo a blood draw\n* Able to provide written informed consent\n\nExclusion Criteria:\n\n* Current use of clonidine or beta-blockers\n* Current smoker or History of smoking in the past 3 months.\n* Hyperlipidemia: Fasting triglycerides \\> 250 mg\u002FdL\n* Currently taking hypertension medication\n* History of heart disease (e.g., myocardial infarction, stent, byass, heart attack, stroke, heart failure, valvular heart disease, cardiomyopathy)\n* History of neurological disorders\n* History of transplant\n* Actively participating in other studies, except for a registry study.","ALL","18 Years","79 Years",{"count":87,"type":88},60,"ESTIMATED","INTERVENTIONAL",[91],"PHASE1","The purpose of this study is to examine the hypothesize that 4 weeks of sympathetic nerve activity (SNA) inhibition (oral clonidine) will cause a significant reduction in circulating blood concentrations and endothelial cell expression of inflammatory markers (e.g., TNF-α, IL-6).\n\nOur study is a prospective study using a randomized, double-blinded design to test 4 weeks of SNA blockade (oral clonidine) compared with a BP-lowering control condition (diuretic, hydrochlorothiazide) or a placebo.",[94,95,96,97,98,99],"Blood Pressure","Diabetes","Obesity","Insulin Resistance","Diuretics Drug Reactions","Sympathetic Nerve Activity","2025-06-04",{"date":102,"type":103},"2025-06-05","ACTUAL",{"date":105,"type":103},"2021-07-01",{"date":107,"type":88},"2027-08-01",{"name":5,"class":6},1]